DEF: Neogen Faces Headwinds, Revamps Executive Pay, and Appoints New CEO

Neogen Corporation announced its 2025 Annual Meeting, detailing executive and board changes, a significant shift in executive compensation strategy following shareholder feedback, and reporting financial performance below expectations due to market and integration challenges.

Summary

• Neogen Corporation will hold its 2025 Annual Meeting of Shareholders virtually on Thursday, October 23, 2025, at 10:00 a.m. Eastern Time.
• Shareholders will vote on the election of four Class II directors, an advisory resolution on executive compensation, and the ratification of BDO USA P.C. as the independent auditor for fiscal year 2026.
• The company reported financial performance below expectations for fiscal year 2025, impacted by a weak end-market, global trade uncertainty, foreign currency headwinds, and challenges from the integration of the former 3M Food Safety Division.
• Key financial metrics for fiscal year 2025 included a net loss of $1,092.0 million and Adjusted EBITDA of $184.2 million, both below prior year and internal targets.
• Following a 48.8% approval rate for the 2024 Say-on-Pay vote, Neogen introduced Performance Share Units (PSUs) for fiscal year 2026 long-term incentive compensation, comprising 50% of the award value, tied to Revenue CAGR, Adjusted EBITDA Margin Expansion, and Free Cash Flow Conversion, with a relative Total Shareholder Return (rTSR) modifier.
• Mikhael Nassif was appointed President and CEO effective August 11, 2025, succeeding John E. Adent, who stepped down.
• David H. Naemura, Chief Financial Officer, also assumed the role of Chief Operating Officer effective January 1, 2025, following the retirement of Douglas E. Jones as COO on February 28, 2025.
• The company completed a refinancing of its term loan and revolving credit facility, extending maturity to 2030 and realizing interest expense savings.
• A divestiture of the global cleaners & disinfectants business was announced and completed subsequent to the fiscal year end.

Sentiment

Score: 3

Explanation: The company reported a substantial net loss and missed key financial targets for fiscal year 2025, indicating significant operational and market challenges. While management is taking steps to address shareholder concerns regarding compensation and integration issues, the immediate financial results are concerning.

Positives

• Successful refinancing of term loan and revolving credit facility, extending maturity to 2030 and realizing interest expense savings.
• Completion of construction for the main Petrifilm production facility and significant equipment installation, marking progress in the final integration workstream of the former 3M Food Safety Division.
• Proactive engagement with shareholders and subsequent implementation of Performance Share Units (PSUs) in the fiscal year 2026 long-term incentive plan, demonstrating responsiveness to feedback and strengthening the link between executive pay and long-term company performance.
• Appointment of new CEO Mikhael Nassif and new COO David H. Naemura, signaling fresh leadership.
• Announcement and completion of the divestiture of the global cleaners & disinfectants business, streamlining the portfolio.

Negatives

• Fiscal year 2025 performance was below expectations, driven by a weak end-market environment, global trade uncertainty, and foreign currency headwinds.
• Reported a net loss of $1,092.0 million in fiscal year 2025, a significant decline from a net loss of $9.4 million in fiscal year 2024, primarily due to a non-cash goodwill impairment charge.
• Adjusted EBITDA decreased to $184.2 million in fiscal year 2025 from $213.2 million in fiscal year 2024.
• Actual Revenue ($895 million) and Free Cash Flow ($(46) million) for fiscal year 2025 were significantly below the Incentive Compensation Plan targets of $960 million and $74 million, respectively.
• Profitability was negatively impacted by challenges related to the integration of the former 3M Food Safety Division, including elevated inventory write-offs and inefficiencies in the relocated sample collection product line.
• The 2024 advisory Say-on-Pay vote received only 48.8% approval, indicating significant shareholder dissatisfaction with executive compensation practices.
• Capital expenditures were elevated in fiscal year 2025 due to ongoing integration investments, negatively impacting cash flow.

Risks

• Weak end-market environment and global trade uncertainty impacting revenue and profitability.
• Foreign currency headwinds affecting financial results.
• Challenges and inefficiencies related to the integration of the former 3M Food Safety Division, including elevated inventory write-offs and difficulties in achieving prior output levels for relocated product lines.
• Lower food production levels due to inflation and changing consumer behavior, influencing the food safety market.
• Decreased cattle herd size in the U.S., impacting the animal safety end market.
• Potential for continued shareholder dissatisfaction with executive compensation if the new PSU structure does not adequately address concerns or if performance remains weak.
• Reliance on the successful execution of the 3M Food Safety Division integration, particularly the Petrifilm production start-up, for future performance.

Future Outlook

The company is focused on improving performance by addressing integration challenges, particularly with the Petrifilm production start-up, and by aligning executive incentives more closely with long-term shareholder value through new performance-based equity awards. The refinancing of debt provides financial flexibility for future operations.

Management Comments

• Our goal for the Annual Meeting is to enable the broadest number of shareholders to participate in the meeting, while providing substantially the same access and exchange with the Board and management as an in-person meeting.
• We appreciate your continued confidence in Neogen and look forward to your participation in our virtual Annual Meeting.
• We are committed to ensuring that our shareholders have substantially the same opportunities to participate in the virtual Annual Meeting as they would at an in-person meeting.
• We listened to and responded to the areas of concern from our shareholders.
• We implemented a robust ICP design for fiscal year 2025 that aligned with our fiscal year budget and held our executives to a high standard of performance.
• Our fiscal year 2026 design will continue to align with the approved fiscal year 2026 budgets that are appropriately challenging and motivating for our NEOs given the markets in which we compete in.
• While we believe stock options, which were 70% of the equity mix for the CEO (60% for other NEOs), are inherently performance-based and 100% aligned with shareholder value, we are introducing Performance Share Units (PSUs) in the fiscal year 2026 long-term plans for NEOs.
• The CEO compensation remained flat for fiscal year 2025, and in fact realized pay decreased as depicted on page 29.
• Over the past three fiscal years, Mr. Adent's overall compensation ranged from 18% to 24% of total SCT total compensation. This is due to all elements of variable pay resulting in payouts less than target, including stock option values that are underwater which demonstrates direct alignment with TSR.

Industry Context

Neogen operates in the global food safety, livestock, and pet health & wellness markets. The filing indicates that the food safety end market was influenced by lower food production levels due to inflation and consumer value-seeking behavior. The animal safety market was impacted by the lowest U.S. cattle herd size in over 70 years. Global trade uncertainty also affected distributor inventory commitments. These factors suggest a challenging operating environment across Neogen's core segments, reflecting broader economic pressures and specific industry dynamics.

Comparison to Industry Standards

• The company's Total Shareholder Return (TSR) has been below the S&P MidCap 400 Health Care Index over the past five fiscal years (2021-2025).
• The fiscal year 2026 PSU design will measure performance against Revenue (CAGR), Adjusted EBITDA margin expansion, and FCF Conversion with a relative TSR modifier, measuring performance against the S&P 600 Healthcare Equipment & Services peer companies.
• The peer group for executive compensation benchmarking includes companies such as 10x Genomics, Mettler-Toledo International, Azenta, Bio-Rad Laboratories, Bio-Techne Corporation, Bruker Corporation, Charles River Laboratories, Exact Sciences Corporation, Guardant Health, IDEXX Laboratories, iRhythm Technologies, Maravai LifeScience Holdings, Natera, NeoGenomics, OraSure Technologies, QuidelOrtho Corporation, Repligen Corporation, Sotera Health Company, and Waters Corporation.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are directly impacted by the significant net loss and below-target financial performance, as well as the company's TSR being below the S&P MidCap 400 Health Care Index. The changes in executive compensation, including the introduction of PSUs, aim to better align executive interests with long-term shareholder value. The virtual annual meeting format is designed to enable broader participation.
• Employees are affected by management changes, including the new CEO and COO appointments. The 401(k) plan and Employee Stock Purchase Plan continue to be available.
• Customers are potentially impacted by integration challenges of the 3M Food Safety Division, which led to inefficiencies in product lines and elevated inventory write-offs, though the completion of the Petrifilm facility aims to improve future supply.
• Creditors are positively impacted by the refinancing of the term loan and revolving credit facility, which extended maturity to 2030, providing greater financial stability.

Next Steps

• Hold the 2025 Annual Meeting of Shareholders on October 23, 2025, to vote on director elections, executive compensation, and auditor ratification.
• Continue to monitor and evaluate the effectiveness of the new performance-based long-term incentive plan (PSUs) for fiscal year 2026.
• Complete the integration of the former 3M Food Safety Division, including the full operationalization of the Petrifilm production facility.
• Continue to seek input from shareholders regarding executive compensation and other strategic matters.
• The Board expects to appoint a new Chair of the Audit Committee, effective October 24, 2025.
• Douglas E. Jones will continue in a part-time capacity providing transition support until December 31, 2025.

Key Dates

Recommendation

The company reported a substantial net loss and missed key financial targets for fiscal year 2025, indicating significant operational and market challenges. While the new CEO appointment, executive compensation reforms (PSUs), and debt refinancing are positive steps towards future improvement and addressing shareholder concerns, the immediate financial performance and ongoing integration risks warrant a cautious 'hold' stance. Investors should monitor the execution of the 3M integration, the impact of new leadership, and the effectiveness of the revised compensation structure on future financial results before considering a 'buy' or 'sell' recommendation.

Keywords

Neogen Corporation, NEOG, SEC Filing, Proxy Statement, Annual Meeting, Executive Compensation, Say-on-Pay, Board of Directors, Corporate Governance, Financial Performance, Adjusted EBITDA, Net Loss, 3M Food Safety Division, Integration Challenges, Performance Share Units, CEO Change, CFO, COO, Shareholder Outreach, Risk Management, Food Safety, Animal Safety, Biotechnology, Diagnostics